<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Candesartan</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00796</strong>&#160; (APRD00420)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Candesartan is an angiotensin-receptor blocker (<span class="caps">ARB</span>) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (<span class="caps">RAAS</span>); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (<span class="caps">ACE</span>) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00796/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00796/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00796.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00796.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00796.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00796.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00796.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00796">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Candesartan cilexetil</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Amias</td><td>Eureco (Netherlands), Takeda (United Kingdom)</td></tr><tr><td>Atacand</td><td>AstraZeneca</td></tr><tr><td>Blopress</td><td>Takeda</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Atacand Plus</td><td>Candesartan Cilexetil + Hydrochlorothiazide</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li>
<li><a href="/mesh/angiotensin-ii-type-1-receptor-blockers">Angiotensin II Type 1 Receptor Blockers</a></li>
<li><a href="/mesh/angiotensin-receptor-antagonists">Angiotensin Receptor Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>139481-59-7</td></tr><tr><th>Weight</th><td>Average: 440.454<br>Monoisotopic: 440.159688536</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>20</sub>N<sub>6</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>HTQMVQVXFRQIKW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Azoles</td></tr><tr><th>Subclass</th><td>Tetrazoles</td></tr><tr><th>Direct parent</th><td>Biphenyltetrazoles and Derivatives</td></tr><tr><th>Alternative parents</th><td>Biphenyls and Derivatives; Benzimidazoles; Benzoic Acids; Benzoyl Derivatives; Alkyl Aryl Ethers; N-substituted Imidazoles; Enolates; Carboxylic Acids; Polyamines</td></tr><tr><th>Substituents</th><td>biphenyl; benzoic acid or derivative; benzimidazole; benzoic acid; benzoyl; alkyl aryl ether; n-substituted imidazole; benzene; imidazole; carboxylic acid derivative; carboxylic acid; ether; enolate; polyamine; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the biphenyltetrazoles and derivatives. These are organic compounds containing a biphenyl attached to a tetrazole. A carbon atom of the biphenyl moiety is boned to a carbon or the nitrogen atom of the tetrazole moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.</td></tr><tr><th>Pharmacodynamics</th><td>Candesartan cilexetil is an ARB prodrug that is rapidly converted to candesartan, its active metabolite, during absorption from the gastrointestinal tract. Candesartan confers blood pressure lowering effects by antagonizing the hypertensive effects of angiotensin II via the RAAS. RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from granular cells of the juxtaglomerular apparatus in the kidneys. Renin cleaves circulating angiotensinogen to angiotensin I, which is cleaved by angiotensin converting enzyme (ACE) to angiotensin II. Angiotensin II increases blood pressure by increasing total peripheral resistance, increasing sodium and water reabsorption in the kidneys via aldosterone secretion, and altering cardiovascular structure. Angiotensin II binds to two receptors: type-1 angiotensin II receptor (AT1) and type-2 angiotensin II receptor (AT2). AT1 is a G-protein coupled receptor (GPCR) that mediates the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Studies performed in recent years suggest that AT2 antagonizes AT1-mediated effects and directly affects long-term blood pressure control by inducing vasorelaxation and increasing urinary sodium excretion. Angiotensin receptor blockers (ARBs) are non-peptide competitive inhibitors of AT1. ARBs block the ability of angiotensin II to stimulate pressor and cell proliferative effects. Unlike ACE inhibitors, ARBs do not affect bradykinin-induced vasodilation. The overall effect of ARBs is a decrease in blood pressure.</td></tr><tr><th>Mechanism of action</th><td>Candesartan selectively blocks the binding of angiotensin II to AT1 in many tissues including vascular smooth muscle and the adrenal glands. This inhibits the AT1-mediated vasoconstrictive and aldosterone-secreting effects of angiotensin II and results in an overall decrease in blood pressure. Candesartan is greater than 10,000 times more selective for AT1 than AT2. Inhibition of aldosterone secretion may increase sodium and water excretion while decreasing potassium excretion.</td></tr><tr><th>Absorption</th><td>Following administration of the candesartan cilexetil prodrug, the absolute bioavailability of candesartan was estimated to be 15%. Food with a high fat content has no affect on the bioavailability of candesartan from candesartan cilexetil.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.13 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>Candesartan is highly bound to plasma proteins (&gt;99%) and does not penetrate red blood cells.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>The prodrug candesartan cilexetil undergoes rapid and complete ester hydrolysis in the intestinal wall to form the active drug, candesartan. Elimination of candesartan is primarily as unchanged drug in the urine and, by the biliary route, in the feces. Minor hepatic metabolism of candesartan (</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Candesartan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00005">O-Deethylated candesartan</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/5">Details</a></td></tr><tr><td>Candesartan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003677" target="_blank">UDP-glucuronosyltransferase 1-3</a></li></ul></td><td><a href="/metabolites/DBMET00006">Candesartan N2-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/6">Details</a></td></tr><tr><td>Candesartan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000017" target="_blank">Prostaglandin G/H synthase 1</a></li></ul></td><td><a href="/metabolites/DBMET00007">Candesartan O-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/7">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>When candesartan is administered orally, about 26% of the dose is excreted unchanged in urine. Candesartan is mainly excreted unchanged in urine and feces (via bile).</td></tr><tr><th>Half life</th><td>Approximately 9 hours.</td></tr><tr><th>Clearance</th><td><ul>
	<li>0.37 mL/min/kg</li>
</ul></td></tr><tr><th>Toxicity</th><td>No lethality was observed in acute toxicity studies in mice, rats and dogs given single oral doses of up to 2000 mg/kg of candesartan cilexetil or in rats given single oral doses of up to 2000 mg/kg of candesartan cilexetil in combination with 1000 mg/kg of hydrochlorothiazide. In mice given single oral doses of the primary metabolite, candesartan, the minimum lethal dose was greater than 1000 mg/kg but less than 2000 mg/kg.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Candesartan Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00158?highlight%5Bcompounds%5D%5B%5D=DB00796&amp;highlight%5Bproteins%5D%5B%5D=DB00796">SMP00158</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8717</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6208</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5186</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.848</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9115</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8266</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7397</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6504</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5594</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.5195</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.889</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5151</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7392</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.7895</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          AMES toxic 
        </td>
        <td>
            0.556
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7561
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9972
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5515 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.794
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.5837
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astrazeneca pharmaceuticals lp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>16 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>32 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>4 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>8 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Atacand 30 4 mg tablet Bottle</td><td>75.98USD</td><td>bottle</td></tr><tr><td>Atacand 30 8 mg tablet Bottle</td><td>74.96USD</td><td>bottle</td></tr><tr><td>Atacand hct 32-25 mg tablet</td><td>3.64USD</td><td>tablet</td></tr><tr><td>Atacand hct 32-12.5 mg tablet</td><td>3.43USD</td><td>tablet</td></tr><tr><td>Atacand 32 mg tablet</td><td>3.36USD</td><td>tablet</td></tr><tr><td>Atacand hct 16-12.5 mg tablet</td><td>3.36USD</td><td>tablet</td></tr><tr><td>Atacand 16 mg tablet</td><td>2.49USD</td><td>tablet</td></tr><tr><td>Atacand 4 mg tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Atacand 8 mg tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Atacand 16 mg Tablet</td><td>1.28USD</td><td>tablet</td></tr><tr><td>Atacand 32 mg Tablet</td><td>1.28USD</td><td>tablet</td></tr><tr><td>Atacand 8 mg Tablet</td><td>1.28USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5534534</td><td>1994-01-09</td><td>2014-01-09</td></tr><tr><td>United States</td><td>5705517</td><td>1994-04-18</td><td>2011-04-18</td></tr><tr><td>Canada</td><td>2083305</td><td>2003-12-09</td><td>2012-11-19</td></tr><tr><td>Canada</td><td>2040955</td><td>1998-02-03</td><td>2011-04-22</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>logP</td><td>6.1</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>7.71e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.02</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>5.05</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.8</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>2.97</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>1.71</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>-1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>118.81</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>134.92</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>45.35</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Marina Etinger, Boris Fedotev, Ben-Zion Dolitzky, &#8220;Preparation of candesartan cilexetil.&#8221; U.S. Patent US20050131037, issued June 16, 2005.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=20050131037&amp;tbm=pts" target="_blank">US20050131037 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the <span class="caps">CHARM</span>-Overall programme. Lancet. 2003 Sep 6;362(9386):759-66. <a href="http://www.ncbi.nlm.nih.gov/pubmed/13678868">Pubmed</a></li>
	<li>Mendis B, Page SR: Candesartan: widening indications for this angiotensin II receptor blocker? Expert Opin Pharmacother. 2009 Aug;10(12):1995-2007. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19563275">Pubmed</a></li>
	<li>Baguet JP, Barone-Rochette G, Neuder Y: Candesartan cilexetil in the treatment of chronic heart failure. Vasc Health Risk Manag. 2009;5(1):257-64. Epub 2009 Apr 8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19436650">Pubmed</a></li>
	<li>Bader, M. (2004). Renin-angiotensin-aldosterone system. In S. Offermanns, &amp; W. Rosenthal (Eds.). <em>Encyclopedic reference of molecular pharmacology</em> (pp. 810-814). Berlin, Germany: Springer.</li>
	<li>Stanfield, C.L., &amp; Germann, W.J. (2008). <em>Principles of human physiology</em> (3 <sup>rd</sup> ed.). San Francisco, CA: Pearson Education, Inc.</li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00626" target="_blank">D00626 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07468" target="_blank">C07468 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2541" target="_blank">2541 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508342" target="_blank">46508342 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.2445.html" target="_blank">2445 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50240609" target="_blank">50240609 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=3347" target="_blank">3347 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1016" target="_blank">CHEMBL1016 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP001442" target="_blank">DAP001442 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA448765" target="_blank">PA448765 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=587" target="_blank">587 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=587" target="_blank">587 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2239091" target="_blank">2239091 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/candesar.htm" target="_blank">http://www.rxlist.com/cgi/generic/candesar.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/candesartan.html" target="_blank">http://www.drugs.com/cdi/candesartan.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Candesartan" target="_blank">Candesartan <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C09CA06<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C09#C09">C09 &#8212; AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</a></li><li><a href="/atc/C09C#C09C">C09C &#8212; ANGIOTENSIN II ANTAGONISTS, PLAIN</a></li><li><a href="/atc/C09CA#C09CA">C09CA &#8212; Angiotensin II antagonists, plain</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:32.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00796.pdf?1265922797">show</a>(49.4 KB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00594">Amiloride</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01395">Drospirenone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>The ARB increases serum levels of lithium</td></tr><tr><td><a href="/drugs/DB01345">Potassium</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00421">Spironolactone</a></td><td>Increased risk of hyperkalemia</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Increased risk of nephrotoxicity</td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>The angiotensin II receptor blocker, Candesartan, may increase the adverse effects of Trandolapril. </td></tr><tr><td><a href="/drugs/DB00374">Treprostinil</a></td><td>Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use. </td></tr><tr><td><a href="/drugs/DB00384">Triamterene</a></td><td>Increased risk of hyperkalemia</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Administer on a regular basis, at about the same time each day.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>